Elevating Health Through Precision Biology
Advancing non-invasive diagnostics through clinically validated biomarker technologies.
What is Elebio?
Precision Biology. Clinical Impact. Global Vision.
Elebio is a biotechnology-driven company advancing precision diagnostics through scientifically validated, non-invasive screening technologies.
Our work spans accredited medical laboratory services, cancer screening research and development, and cross-border clinical collaboration, with a focus on enabling earlier risk assessment and more informed clinical decision-making.
Backed by a multidisciplinary team of scientists, clinicians, and regulatory specialists, Elebio integrates biology, data science, and clinical evidence to deliver reliable diagnostic solutions across Hong Kong, the Greater Bay Area, and selected international markets.
What We Do
Medical Laboratory Services
Provision of accredited medical laboratory testing services, supporting clinicians with accurate, reliable diagnostic data in Hong Kong.
Diagnostic R&D
Research and development of non-invasive cancer screening technologies, translating scientific discoveries into clinically meaningful solutions.
Regional Expansion & Partnerships
Strategic collaborations with hospitals, medical platforms, insurers, and research institutions to expand access across Hong Kong, Greater Bay Area, and international markets.
Core Technology Highlight (PURE Index®)
PURE Index® is a urine-based, non-invasive risk assessment designed to support clinical decision-making for patients with elevated PSA levels.
Developed by a multidisciplinary team of scientists and urologists, PURE Index® integrates urinary biomarkers and clinical data to stratify prostate cancer risk — helping clinicians identify patients who may benefit from further evaluation while reducing unnecessary invasive procedures.
Why PURE Index® Matters
The Challenge
PSA screening alone has limited specificity.
Approximately 3 out of 4 men with elevated PSA levels undergo unnecessary prostate biopsies, exposing patients to avoidable risks and anxiety.
Our Approach
PURE Index® provides additional biological insight by analysing urinary biomarkers alongside clinical information.
By improving risk stratification, PURE Index® supports more informed biopsy decisions, enhances clinical confidence, and helps reduce unnecessary invasive procedures.
Metrics
Services & Collaboration
Elebio actively collaborates with hospitals, medical centres, laboratories, insurance providers, and research institutions to expand access to innovative diagnostic solutions.
Research & Publications
Elebio’s technologies are supported by ongoing clinical studies and collaborative research across Hong Kong, Mainland China, and international partners.
Selected publications, clinical data updates, and research highlights will be released progressively.
Partner with Elebio
We welcome collaboration with medical institutions, laboratories, and healthcare partners committed to advancing precision cancer screening.